TY - JOUR T1 - <em>Mycoplasma genitalium</em> macrolide and fluoroquinolone resistance in pregnant women in Papua New Guinea JF - Sexually Transmitted Infections JO - Sex Transm Infect SP - 71 LP - 72 DO - 10.1136/sextrans-2022-055552 VL - 99 IS - 1 AU - Marinjho E Jonduo AU - Andrew J Vallely AU - David M Whiley AU - Michaela A Riddell AU - William Pomat AU - Nicola Low AU - Emma L Sweeney Y1 - 2023/02/01 UR - http://sti.bmj.com/content/99/1/71.abstract N2 - Mycoplasma genitalium is a sexually transmitted bacterium that colonises the human urogenital tract and in pregnant women has been associated with adverse pregnancy and birth outcomes.1 In pregnancy, the prevalence of M. genitalium is estimated to be 0.9% (95% CI 0.6% to 1.4%) in high-income settings and 12.5% in individual studies in low- and middle-income-countries.1 2 Globally, M. genitalium antimicrobial resistance (AMR) continues to escalate,3 and despite rising rates of AMR the prevalence of macrolide and fluoroquinolone resistance in M. genitalium has not been widely studied among pregnant women.2 Treatment of M. genitalium during pregnancy with selected antimicrobials such as macrolides is recommended, while tetracyclines are contraindicated and caution is recommended for fluoroquinolones,4 highlighting the potential issues surrounding available/effective antibiotics for this pathogen during pregnancy. In Papua New Guinea (PNG), macrolides and fluoroquinolones are routinely used for treatment of STIs4 and hence we aimed to characterise M. genitalium AMR in pregnant women.We screened 69 M. genitalium-positive urine samples obtained from women attending their first antenatal clinic visit at five health facilities in Madang Province (PNG) between 2018 and 2019, enrolled in the control arm of a randomised controlled trial in PNG, the Women And Newborn Trial of Antenatal Interventions and Management.5 Confirmatory PCR was performed to verify the presence of M. genitalium … ER -